Annika Freiberger

Dr. Annika Freiberger


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2022 in Cardiovascular Diagnosis and Therapy
Verified
Journal Article
Open access
PDF file
AFAnnika Freiberger
Annika Freiberger
JBJürGen Beckmann
JürGen Beckmann
SFSebastian Freilinger
Sebastian Freilinger
HKHarald Kaemmerer
Harald Kaemmerer
MHMaximilian Huber
Maximilian Huber
CACaroline Andonian
Caroline Andonian
Original Article Psychosocial well-being in postpartum women with congenital heart disease Annika Freiberger, Jürgen Beckmann, Sebastian Freilinger, Harald Kaemmerer, Maximilian Huber, Nicole Nagdyman, Peter Ewert, Lars Pieper, Charlotte Deppe, Bettina Kuschel, Caroline Andonian

18 July 2023 in The American Journal of Cardiology
Verified
Journal Article
Closed access
AFAnnika Freiberger
Annika Freiberger
CRCristina Richter
Cristina Richter
MHMaximilian Huber
Maximilian Huber
Jürgen BeckmannJürgen Beckmann
Jürgen Beckmann
SFSebastian Freilinger
Sebastian Freilinger
CACaroline Andonian-Dierks
Caroline Andonian-Dierks

Verified
Journal Article
Open access
PDF file
FPFelix Pieringer
Felix Pieringer
MSMathieu Suleiman
Mathieu Suleiman
AKAnn-Sophie Kaemmerer
Ann-Sophie Kaemmerer
ODOliver Dewald
Oliver Dewald
AFAnnika Freiberger
Annika Freiberger
FHFrank Harig
Frank Harig
Background: Heart rate variability (HRV) is an established, non-invasive parameter for the assessment of cardiac autonomic nervous activity and the health status in general cardiology. However, there are few studies on HRV in adults with congenital heart defects (CHDs). The aim of the present study was to evaluate the use of long-term continuous HRV measurement for the assessment of global health status in adults with cyanotic CHD. Methods: This prospective study included 45 adults (40% female, mean age = 35.2 ± 9.2 [range: 19–58] years) after cardiac surgical repair. HRV parameters were calculated from continuous 24 h measurements using a Bittium Faros 180 sensor (Bittium Corp., Oulu, Finland). Results: Postoperative patients with transposition of the great arteries (TGA) (n = 18) achieved significantly higher values of standard deviation of NN intervals (SDNN) (175.4 ± 59.9 ms vs. 133.5 ± 40.6 ms; p = 0.013) compared with patients with other conotruncal anomalies (n = 22). Comparing patients with TGA after a Senning–Brom or Mustard operation (n = 13) with all other heart surgery patients (n = 32), significantly higher HRV parameters were found after atrial switch (root mean square of successive RR interval differences: 53.6 ± 20.7 ms vs. 38.4 ± 18.3 ms; p = 0.019; SDNN: 183.5 ± 58.4 ms vs. 136.3 ± 45.3 ms; p = 0.006). A higher SDNN was also measured after Senning–Brom or Mustard operations than after a Rastelli operations (n = 2) (SDNN: 183.5 ± 58.4 ms vs. 84.5 ± 5.2 ms; p = 0.037). When comparing atrial switch operations (n = 3) with Rastelli operations, the SDNN value was significantly shorter in the Rastelli group (p = 0.004). Conclusions: Our results suggest that continuous HRV monitoring may serve as a marker of cardiac autonomic dysfunction in adults with cyanotic CHD after surgical repair. Impaired cardiac autonomic nervous activity may be associated with an increased risk of adverse reactions in patients with repaired CHD. Therefore, a longitudinal assessment of HRV patterns and trends may provide a deeper insight into dynamic changes in their autonomic regulation and disease progression, lifestyle changes, or treatments. As each person has individual variability in heart rate, HRV may be useful in assessing intra-individual disease progression and may help to improve personalized medicine. Further studies are needed to better understand the underlying mechanisms and to explore the full potential of HRV analysis to optimize medical care for ACHDs.

1 December 2022 in Cardiovascular Diagnosis and Therapy
Verified
Journal Article
Open access
PDF file
AFAnnika Freiberger
Annika Freiberger
ABAmely Busse
Amely Busse
PEPeter Ewert
Peter Ewert
MHMichael Huntgeburth
Michael Huntgeburth
HKHarald Kaemmerer
Harald Kaemmerer
CACaroline Andonian
Caroline Andonian
Background: Pulmonary vascular disease and pulmonary hypertension (PH) belong to the most relevant complications of congenital heart disease (CHD) in the long-term course. Although PH might lead to a severely impaired quality of life (QOL), there are no current studies comparing QOL in adults with CHD (ACHD) with and without PH. Therefore, this study aimed to systematically examine QOL in ACHD with and without PH in order to generate a more differentiated understanding of their overall health-status and to employ newly gained findings into general care of this particular patient population. Methods: In this comparative cross-sectional study, a representative sample of 803 adults with various forms of CHD with or without PH was analyzed. Data collection took place between September 2017 until February 2018 in a tertiary care center for ACHD. Medical data was retrieved from medical records. QOL was assessed using the EQ-5D-5L questionnaire. Descriptive methods, chi-square and t-tests were used to compare QOL of patients with and without PH. Results: Of 803 patients, 752 patients had no PH [93.6%; 47.3% female; mean age: 34.9±11.83 (range, 18–86) years], 51 were identified with manifest PH [6.4%; 55.8% female; mean age: 41.9±12.17 (range, 21–69) years]. PH patients showed significantly worse overall QOL [mean no PH: 86.78±13.30 (8.2–100) vs. mean PH: 81.79±12.77 (43.6–100); 95% confidence interval (CI): 1.43 to 9.46; P=0.013], worse crosswalk index [mean no PH: 93.29±12.86 (−11, 100) vs. mean PH: 89.73±11.77 (47–100); 95% CI: 0.08 to 7.56; P=0.043], and worse VAS [mean no PH: 80.12±16.50 (15–100) vs. mean PH: 72.56±16.80 (40–100); 95% CI: 3.29 to 12.17; P=0.004]. However, after adjusting for age, only the VAS stayed significant (P=0.039). The QOL within the dimensions mobility (P<0.001), self-care (P=0.002), and usual activities (P=0.007), were significantly decreased in PH patients. Overall, anxiety and depression (11.08%) as well as pain and discomfort (11.03%) were the most impaired dimensions in both patient groups. Conclusions: Since QOL is a significant predictor of outcome, PH-CHD patients need an early provision of psychosocial, health promoting support in addition to dedicated care and targeted PH treatment. It is therefore pivotal to timely identify unique psychosocial impairments in order to enhance quantity and QOL in this particularly vulnerable patient population.

12 November 2024 in International Journal of Behavioral Medicine
Verified
Journal Article
Open access
PDF file
AFAnnika Freiberger
Annika Freiberger
CACaroline Andonian-Dierks
Caroline Andonian-Dierks
JBJürgen Beckmann
Jürgen Beckmann
SFSebastian Freilinger
Sebastian Freilinger
PEPeter Ewert
Peter Ewert
MHMaximilian Huber
Maximilian Huber
Background: Due to various reasons explored in previous studies, adults with congenital heart disease (ACHD) are at risk of developing post-traumatic stress symptoms (PTSS). The aim of this study is to explore multiple potential psychosocial protective factors in ACHD and to understand their role in different complexities of congenital heart disease (CHD) and PTSS. Method: This study was part of the “ABS-AHF” study, where 234 ACHD were recruited from November 2021 to August 2022 at a tertiary CHD care center. Data were collected on PTSS (PDS), resilience (RS-13), sense of coherence (SOC-L9), and social support (F-SozU K-14). Results: The mean scores were 70.55 + / − 12.31 [21–91] for resilience, 35.83 + / − 4.81 [15–60] for sense of coherence (SOC), and 4.30 + / − 0.79 [0.93–5] for social support. SOC (OR, .91; p = .024 [.84; 9.98]) and social support (OR, .48; p = .001 [.29; 7.96]) were shown to reduce the likelihood of PTSS. Low resilience (OR, 2.40, p = .0248 [1.18; 5.18]) seems to increase this likelihood. Conclusion: Integrating parents and relatives early on seems to be an important protective resource. Parental support in childhood affects the development of SOC which is in line with social support related to lower PTSS. With regard to resilience and SOC, a brief and manageable screening option for personal resources is available to refer potentially vulnerable patients to specialized psychosocial care. Care offers should address coping styles and life with CHD. Offering multidisciplinary care, integrating the patient’s social network, and education for patients to increase resilience and SOC might provide a way to enhance psychosocial outcomes, quality of life, and adherence in ACHD.

20 November 2025 in Geriatrics
Verified
Journal Article
Open access
PDF file
AKAnn-Sophie Kaemmerer-Suleiman
Ann-Sophie Kaemmerer-Suleiman
FHFrank Harig
Frank Harig
AFAnnika Freiberger
Annika Freiberger
ODOliver Dewald
Oliver Dewald
SAStephan Achenbach
Stephan Achenbach
FMFritz Mellert
Fritz Mellert
Background: Advances in diagnosis and treatment have led to a growing population of adults with congenital heart disease (ACHD). Despite increasing life expectancy, their clinical needs—especially in older age—remain poorly defined. Cardiac and non-cardiac comorbidities are prevalent, and emerging evidence suggests accelerated biological aging compared to the general population. However, data on older patients and geriatric patients with CHD are limited. Objectives: This study aimed to characterize patients with CHD aged ≥50 years, focusing on functional status, comorbidities, sex-specific differences, and therapeutic patterns. Methods: The PATHFINDER-CHD Registry is a prospective, observational, multicenter registry enrolling patients with CHD with manifest heart failure (HF), HF history, or high HF risk. Data include anatomy, prior treatments, comorbidities, and medication use. Results: Among 1935 patients, 297 were ≥50 years old. Most had acyanotic CHD (62%); Tetralogy of Fallot (21%) was the most frequent diagnosis. A morphologic right systemic ventricle was present in 12%, and 5% had univentricular hearts. HF was manifest in 21%; 44% were classified as ACC/AHA stage B, 51% as stage C, yet 77% were in Perloff class I/II. Common cardiovascular comorbidities included aortopathy (55%), hypertension (37%), and arrhythmia (33%). Non-cardiac comorbidities included thyroid dysfunction (25%), renal impairment (18%), and neurological disease (13%). Sex-specific differences were observed. Despite HF burden, SGLT2 inhibitors and ARNIs were used in only 17% and 8.4%, respectively. Conclusions: Older patients with CHD represent a clinically complex cohort with high comorbidity burden. The findings support the concept of accelerated aging and emphasize the need for tailored interdisciplinary care strategies.